News Tag: 2022 newsletters

FORTE STUDY UPDATE: NRG-CC005/FORTE Trial Communications

Read More

A Randomized Phase II Trial of Immunotherapy with Dual Immune Checkpoint Inhibitors Compared to Anti-PD1 Monotherapy in Patients with Deficient Mismatch Repair System Recurrent Endometrial Carcinoma (NRG-GY025)

Read More

A Study Champion Perspective: Christina Henson, MD

Read More

Upcoming Trial Highlight: Studying Stereotactic Radiosurgery Before Versus After Surgery for Patients with Resectable Brain Metastases (NRG-BN012)

Read More

NRG-BN011 Seeks to Improve Treatment Outcomes in a Substantial Subset of Glioblastoma Patients with Dual Alkylating Therapy

Read More

A Safety Run-in and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma (NRG-BN010)

Read More

FORTE STUDY UPDATE: NRG-CC005 (The FORTE Study)

Read More

Testing ctDNA as a Biomarker for Adjuvant Therapy Intensity in Stage 3 Colon Cancer (NRG-GI008, The “CIRCULATE-US” Study)

Read More

April is National Cancer Control Month: NRG Protocol Support Committee Column

Read More

Exploring Options to Potentially Improve Treatment and Quality of Life for Patients in Two Head and Neck Cancer Trials

Read More